OIT (oral immunotherapy) and SLIT (sublingual) is still in a clinical research stage for food allergies; however, a small subset of doctors do currently offer it in their own practice outside of the research setting (see oit101.org). Some of these practitioners do tell patients at some point that they have achieved "sustained unresponsiveness." Most allergists do not yet offer it as there is no standardized protocol for it, it's not considered "standard of care."
The first food allergy OIT product, Palforzia, released last year. It's claim to fame (and competitive moat) is the combination of them sponsoring a series of large trial using the same, standardized protocol which now has become part of the drug labeling, so physicians don't have to decide themselves, as well as a exclusive supply agreement for peanut flour that is characterized so each pre-measured capsule has a known amount of protein rather than just a known amount of flour.
From what I remember, SCIT (sub-cutaneous allergy shots) have generally not performed very favorably in research for food allergies; they cause too many severe adverse reactions and they are not anyone's favorite anyway.
The first food allergy OIT product, Palforzia, released last year. It's claim to fame (and competitive moat) is the combination of them sponsoring a series of large trial using the same, standardized protocol which now has become part of the drug labeling, so physicians don't have to decide themselves, as well as a exclusive supply agreement for peanut flour that is characterized so each pre-measured capsule has a known amount of protein rather than just a known amount of flour.
From what I remember, SCIT (sub-cutaneous allergy shots) have generally not performed very favorably in research for food allergies; they cause too many severe adverse reactions and they are not anyone's favorite anyway.